Bayesian Capital Management, LP Corcept Therapeutics Inc Transaction History

Bayesian Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $589,175 - $766,765	27,923 New	27,923 $703,000
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $272,625 - $419,424	12,409 New	12,409 $338,000
Q4 2020 Feb 12, 2021	SELL	$16.78 - $27.3 $470,796 - $765,956	-28,057 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$12.46 - $19.98 $349,590 - $560,578	28,057 New	28,057 $488,000
Q2 2020 Aug 14, 2020	SELL	$11.0 - $18.26 $213,400 - $354,244	-19,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$10.11 - $14.04 $67,747 - $94,082	6,701 Added 52.77%	19,400 $231,000
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $153,149 - $215,375	12,699 New	12,699 $154,000
Q4 2017 Feb 12, 2018	SELL	$15.77 - $20.72 $231,819 - $304,584	-14,700 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $180,810 - $283,710	14,700	14,700 $284,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.16B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.